Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances

Journal of Neural Transmission

Volumn 116, Issue 10, 2009, Pages 1257-1266

  Perez V ^a,b   Marin, C ^c,d   Rubio, A ^a   Aguilar, E ^c   Barbanoj, M ^a   Kulisevsky, J ^a,b  

^a L'Hospital de la Sta Creu i de Sant Pau   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

6 OHDA; DSP 4; Dyskinesias; Parkinson; Rat; Working memory

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; LEVODOPA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC SYSTEM; DYSKINESIA; EXPERIMENTAL RAT; MALE; MEMORY DISORDER; NERVE DEGENERATION; NONHUMAN; NORADRENERGIC SYSTEM; PARKINSONISM; PRIORITY JOURNAL; RAT; TASK PERFORMANCE; WORKING MEMORY;

ANIMALS; BENZYLAMINES; COGNITION DISORDERS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; LOCUS COERULEUS; MALE; MAZE LEARNING; MEDIAL FOREBRAIN BUNDLE; MEMORY, SHORT-TERM; MOTOR ACTIVITY; NEURODEGENERATIVE DISEASES; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 70349257159     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-009-0291-0     Document Type: Article

References (85)

1. GE Alexander MD Crutcher 1990 Functional architecture of basal ganglia circuits: neural substrates of parallel processing Trends Neurosci 13 266 271
2. GE Alexander MR DeLong PL Strick 1986 Parallel organization of functionally segregated circuits linking basal ganglia and cortex Annu Rev Neurosci 9 357 381
3. T Archer A Fredriksson 2000 Effects of clonidine and alpha-adrenoreceptor antagonists on motor activity in DSP-4 treated mice: dose-, time- and parameter-dependency Neurotox Res 4 235 247
4. T Archer A Fredriksson 2006 Influence of noradrenaline on MPTP-induced deficits in mice J Neural Transm 113 1119 1129
5. T Archer SO Ogren G Johansson SB Ross 1982 DSP-4 induced two-active avoidance impairment in rats: involvement of central and not peripheral noradrenaline depletion Psychopharmacology 76 303 309
6. AF Arnsten 2001 Modulation of prefrontal cortical-striatal circuits: relevance to therapeutic treatments for Tourette syndrome and attention-deficit hyperactivity disorder Adv Neurol 85 333 341
7. AF Arnsten P Goldman-Rakic 1985 Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged non-human primates Science 230 1273 1276
8. AF Arnsten BM Li 2005 Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions Biol Psychiatry 57 1377 1384
9. RA Avery JS Franowicz C Studholme CH van Dyck AFT Arnsten 2000 The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task Neuropsychoparmacology 23 240 249
10. A Baddeley 1992 Working memory Science 255 556 559
11. A Bechara H Damasio D Tranel S Anderson 1998 Dissociation of working memory from decision making within the human prefrontal cortex J Neurosci 18 428 437
12. MI Bellissimo I Kouzmine MM Ferro BH de Oliveira NS Canteras C Da Cunha 2004 Is the unilateral lesion of the left substantia nigra pars compacta sufficient to induce working memory impairment in rats? Neurobiol Learn Mem 82 150 158
13. CW Berridge BD Waterhouse 2003 The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes Brain Res Rev 42 33 84
14. G Bing Y Zhang Y Watanabe BS McEwen EA Stone 1994 Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra Brain Res 668 261 265
15. R Braga I Kouzmine NS Canteras C Da Cunha 2005 Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats Exp Neurol 192 134 141
16. TJ Brozoski R Brown RE Rosvold PS Goldman 1979 Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkeys Science 205 929 931
17. A Brück R Portin A Lindell A Laihinen J Bergman M Haaparanta O Solin JO Rinne 2001 Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the cudate nucleus Neurosci Lett 311 81 84
18. M Casas G Prat P Robledo M Barbanoj J Kulisevsky F Jane 1999 Scopolamine prevents tolerance to the effects of caffeine on rotational behavior in 6-hydroxydopamine-denervated rats Eur J Pharmacol 366 1 11 (Pubitemid 29076714)
19. MA Cenci CS Lee A Björklund 1998 l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur J Neurosci 10 2694 2706
20. KR Chaudhuri DG Healy AH Schapira 2006 Non-motor symptoms of Parkinson's disease: diagnosis and management Lancet Neurol 5 235 245
21. AL Cheesman RA Barker SJ Lewis TW Robbins AM Owen DJ Brooks 2005 Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease J Neurol Neurosurg Psychiatry 76 1204 1210
22. GL Collingridge TA James NK MacLeod 1979 Neurochemical and electrophysiological evidence for a projection from the locus coeruleus to the substantia nigra J Physiol 290 44P1:STN:280:DyaE1M3ktFKgug%3D%3D
23. P Collins LS Wilkinson BJ Everitt TW Robbins AC Roberts 2000 The effect of dopamine depletion from the cudate nucleus of the common marmoset (Callithrix jacchus) on tests of prefrontal cognitive function Behav Neurosci 114 3 17
24. C Colosimo A Craus 2003 Noradrenergic drugs for levodopa-induced dyskinesia Clin Neuropharmacol 26 299 305
25. R Cools 2008 Role of dopamine in the motivational and cognitive control of behavior Neuroscientist 14 381 395
26. JA Cooper HJ Sagar SM Doherty N Jordan P Tidswell EV Sullivan 1992 Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients Brain 115 1701 1725
27. GC Cotzias MH Van Woert LM Schiffer 1967 Aromatic amino acids and modification of parkinsonism N Engl J Med 276 374 379
28. C Da Cunha MS Gevaerd MA Vital E Miyoshi R Andreatini R Silveira RN Takahashi NS Canteras 2001 Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia Behav Brain Res 124 9 18
29. C Da Cunha ME Angelucci NS Canteras S Wonnacott RN Takahashi 2002 The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities Cell Mol Neurobiol 22 227 237
30. K Del Tredici U Rüb RA De Vos JR Bohl H Braak 2002 Where does Parkinson's disease pathology begin in the brain? J Neuropathol Exp Neurol 61 413 426
31. B Dubois B Pillon 1997 Cognitive deficits in Parkinson's disease J Neurol 244 2 8
32. H Ehringer O Hornykiewicz 1960 Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human and their behavior in diseases of the extrapyramidal system Klin Wochenschr 38 1236 1239
33. P Elsinger L Grattan 1993 Frontal lobe and frontal-striatal substrates for different forms of human cognitive flexibility Neuropsychologia 31 17 28
34. B Faw 2003 Pre-frontal executive committee for perception working memory, attention, long-term memory, motor control, and thinking Conscious Cogn 12 83 139
35. F Fornai AB di Poggio A Pellegrini S Ruggierei A Paparelli 2007 Noradrenaline in parkinson's disease: from disease progression to current therapeutics Curr Med Chem 14 2330 2334
36. LS Forno 1996 Neuropathology of Parkinson's disease J Neuropathol Exp Neurol 55 259 272
37. SH Fox B Henry MP Hil D Peggs AR Crossmand JM Brotchie 2001 Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from th effects of the alpha(2) adrenoceptor antagonist idazoxan Mov Disord 16 642 650
38. JS Franowicz LE Kessler CM Borja BK Kobilka LE Limbird AF Arnsten 2002 Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine J Neurosci 22 8771 8777
39. JM Fritschy R Grzanna 1989 Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals Neuroscience 30 191 197
40. F Fulceri F Biagioni M Ferrucci G Lazzeri A Bartalucci V Galli S Ruggieri A Paparelli F Fornai 2007 Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons Brain Res 1135 219 229
41. JDE Gabrieli J Singh GT Stebbins CG Goetz 1996 Reduced working memory span in Parkinson's disease: evidence for he role of a frontostriatal system in working and strategic memory Neurospychology 10 322 332
42. SB Glickstein PR Hof C Schmauss 2002 Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits J Neurosci 22 5619 5629
43. WP Goldman JD Baty VD Buckles S Sahrmann JC Morris 1998 Cognitive and motor functioning in Parkinson disease: subjects with and without questionable dementia Arch Neurol 55 674 680
44. P Goldman-Rakic 1992 Dopamine-mediated mechanism of the prefrontal cortex Semin Neurosci 4 149 159
45. J Grenhoff M Nisell S Ferré G Aston-Jones TH Svensson 1993 Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat J Neural Transm Gen Sect 93 11 25
46. W Gsell I Strein U Krause P Riederer 1997 Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease-a comparative review J Neural Transm Suppl 51 145 159
47. O Hornykiewicz 1982 Imbalance of brain monoamines and clinical disorders Prog Brain Res 55 419 429
48. O Hornykiewicz SJ Kish 1987 Biochemical pathophysiology of Parkinson's disease Adv Neurol 45 19 34
49. Hornykiewicz O, Pifl C (1994) The validity of the MPTP primate model from neurochemical pathology of idiopathic Parkinson's disease. In: Briley M, Marien M (eds) Noradrenergic mechanisms in Parkinson's disease. CRC Press, Boca Raton, pp 59-71
50. SJ Huber HG Schulman GW Paulson EC Shuttleworth 1987 Fluctuations in plasma dopamine level impair memory in Parkinson's disease Neurology 37 1371 1375
51. BE Jones RY Moore 1977 Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study Brain Res 127 25 53
52. BE Jones TZ Yang 1985 The efferent projections from the reticular formation and the locus coeruleus studied by anterograde and retrograde axonal transport in the rat J Comp Neurol 242 56 92
53. J Kulisevsky 2000 Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease Drugs Aging 16 365 379
54. J Kulisevsky A Avila M Barbanoj R Antonijoan ML Berthier A Gironell 1996 Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels Brain 119 2121 2132
55. J Kulisevsky C García-Sánchez ML Berthier M Barbanoj B Pascual-Sedano A Gironell A Estévez-González 2000 Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients Mov Disord 15 613 626
56. SJ Lewis A Dove TW Robbins RA Barker AM Owen 2003 Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry J Neurosci 23 6351 6356
57. B-M Li Z-T Mei 1994 Delayed response deficit induced by local injection of the alpha-2 adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys Behav Neural Biol 62 134 139
58. BM Li ZM Mao M Wang ZT Mei 1999 Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys Neuropsychopharmacology 21 601 610
59. RM Marié L Barré B Dupuy F Viader G Defer JC Baron 1999 Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease Neurosci Lett 260 77 80
60. C Marin E Aguilar M Bonastre 2008 Effect of locus coeruleus denervation on levodopda-induced moor fluctuations in hemiparkinsonian rats J Neural Transm 115 1133 1139
61. CD Marsden JD Parkes 1977 Success and problems of long-term levodopa therapy in Parkinson's disease Lancet 1 345 349
62. ST Mason HC Fibiger 1979 Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase J Comp Neurol 187 703 724
63. M Mavridis AD Degryse AJ Lategan MR Marien FC Colpaert 1991 Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease Neuroscience 41 507 523
64. E Miyoshi S Wietzikoski M Camplessei R Silveira RN Takahashi C Da Cunha 2002 Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions Brain Res Bull 58 41 47
65. H Narabayashi 1983 Pharmacological basis of akinesia in Parkinson's disease J Neural Transm Suppl 19 143 151
66. K Nishi T Kondo H Narabayashi 1991 Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by l-Dopa Neurosci Lett 123 244 247
67. JA Obeso MC Rodriguez-Oroz M Rodriguez JL Lanciego J Artieda N Gonzalo CW Olanow 2000 Pathophysiology of the basal ganglia in Parkinson's disease Trends Neurosci 23 S8 S19
68. CW Olanow JA Obeso 2000 Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors Neurology 55 Suppl 4 S72 S77
69. SM Papa TM Engber AM Kask TN Chase 1994 Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration Brain Res 662 69 74
70. B Pascual-Sedano J Kulisevsky M Barbanoj C García-Sánchez A Campolongo A Gironell J Pagonabarraga I Gich 2008 Levodopa and executive performance in Parkinson's disease: a randomized study J Int Neuropsychol Soc 14 832 841
71. V Pérez V Sosti A Rubio M Barbanoj J Rodriguez-Alvarez J Kulisevsky 2007 Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration Eur J Pharmacol 576 83 90
72. C Pifl G Schingnitz O Hornykiewicz 1991 Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey Neuroscience 44 591 605
73. Pillon B, Boller F, Levy R, Dubois B (2001) Cognitive deficits in Parkinson's disease. In: Boller F, Grafman J (eds) Handbook of neuropsychology, vol 6. Elsevier, Amsterdan, pp 311-371
74. W Poewe 2008 Non-motor symptoms in Parkinson's disease Eur J Neurol 15 14 20
75. O Rascol I Arnulf H Peyro-Sain Paul C Brefel-Courbon M Vidailhet C Thalamas AM Bonnet S Descombes B Bejjani N Fabre JL Montastruc Y Agid 2001 Idazoxan and alpha-2 antagonist, and L-Dopa-induced dyskinesias in patients with Parkinson's disease Mov Disord 16 708 713
76. M Riekkinen P Jäkälä K Kejonen JR Riekkinen 1999 The alpha-2 agonist, clonidine, improves spatial working memory performance in Parkinson's disease Neuroscience 92 983 989 (Pubitemid 29287543)
77. ZL Rossetti S Carboni 2005 Noradrenaline and dopamine elevations in the rat prefrontal cortex in spatial working memory J Neurosci 25 2322 2329
78. JM Savola M Hill M Engstrom H Merivuori S Wurster SG McGuire SH Fox AR Crossman JM Brotchie 2003 Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinsons' disease Mov Disord 18 872 883
79. J Srinivasan WJ Schmidt 2003 Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats Eur J Neurosci 17 2586 2592
80. J Srinivasan WJ Schmidt 2004 Functional recovery of locus coeruleus noradrenergic neurons after DSP-4 lesion: effects on dopamine levels and neuroleptic induced-parkinsonian symptoms in rats J Neural Transm 111 13 26
81. A Taylor J Saint-Cyr AE Lang 1990 Memory and learning in early Parkinson's disease: evidence for a frontal lobe syndrome Brain Cogn 2 211 238
82. M Wang BP Ramos CD Paspalas Y Shu A Simen A Duque S Vijayraghavan A Brennan A Dudley E Nou JA Mazer DA McCormick AF Arnsten 2007 Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex Cell 129 397 410
83. CH Williams-Gray T Foltynie CEG Brayne TW Robbins RA Barker 2007 Evolution of cognitive dysfunction in an incident Parkinson's disease cohort Brain 130 1787 1798
84. J Xin-Chun MA Chao-Lin LI Bao-Ming 2007 The alpha-2A-adrenoceptor guanfacine improves spatial learning but not fear conditioning rats Acta Physiol Sin 59 739 744
85. C Zarow SA Lyness JA Mortimer HC Chui 2003 Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson's diseases Arch Neurol 60 337 341